Treatment of canine haemangiosarcoma with suberoylanilide hydroxamic acid, a histone deacetylase inhibitor

摘要: A case report is presented by describing the treatment of a 12-year-old dog - diagnosed with haemangiosarcoma (HSA) suberoylanilide hydroxamic acid (SAHA), histone deacetylase (HDAC) inhibitor. The drug was administered orally, on daily basis, approximately 2 weeks post-splenectomy at dose 3 mg kg(-1). HSA lethal malignancy endothelium, which usually disseminated time it diagnosed. Median survival time, usually, no longer than 80 days. Following SAHA, sign malignant growth could be discerned means diagnostic abdominal ultrasound, chest X-ray or help clinical symptoms, over period >1000 precise mechanism HDAC inhibitors exert their anti-cancer effects uncertain, but evidence suggests that exposure to SAHA generates hyperacetylated chromosomal histones, which, in turn, facilitates expression tumour suppressor genes turned off epigenetic mechanisms during neoplastic transformation endothelium.